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12,13 One of these, bisoprolol / hydrochlorohe goal of drug therapy for hypertension, as with any pharmacologic intervention, is to achieve the desired therapeutic response without producing toxicity -maximizing efficacy yet minimizing untoward side effects. The rec-thiazide, contains a low dose of a diuretic and a bblocker. The combination is an effective antihypertenommended approach advocates beginning with a low dose of a single agent, which is then titrated upward sive drug; the low dose of each constituent minimizes the potential for adverse effects. as needed. 1 -5 However, monotherapy is successful in only 50% to 60% of instances 6, 7 because multiple CONVENTIONAL DOSE DIURETIC/b-BLOCKER mechanisms are involved in the pathogenesis of es-FORMULATIONS sential hypertension, and a single drug class may not interdict all offending pathways. Also, as higher doses Diuretics and b-blockers are appropriate agents to of individual drugs are administered, there is an in-combine in hypertension treatment because they creased likelihood of producing untoward side effects lower blood pressure more effectively in combination and stimulating the body's compensatory mecha-than when either is used as monotherapy. The bnisms, which may partially attenuate the incremental blocker can counteract diuretic-induced rises in gain in efficacy.
plasma renin activity 14 and sympathetic nervous sysDiuretics and b-adrenergic blocking drugs are the tem outflow, while modifying diuretic-induced hypoonly two classes of antihypertensive drugs that have kalemia ( Figure 1 ) . been tested and shown to reduce morbidity and mor-A large number of fixed-dose diuretic / b-blocker tality. They have been recommended as preferred ini-formulations are commercially available using contial therapy in patients with systemic hypertension. 5 ventional doses of thiazides ( hydrochlorothiazide They are often combined to maximize blood pressure [ HCTZ ] , 25 to 50 mg daily ) and various b-blockers control either as separate agents or in single fixed-( labetalol, metoprolol, propranolol, extended-release dose formulations. 7 -11 The advantages of a single propranolol, and timolol ) , as well as 5 mg benfixed-dose formulation are the simplicity and conve-droflumethiazide with nadolol, and 25 mg chlorthalinience of use, which lead to improved patient compli-done with atenolol ( Table 1 ) .
15 Recent reports have ance and possible reduction in cost. The possible dis-suggested that these fixed-dose formulations can be advantages include a reduced flexibility in dosage and used as initial therapy in hypertension treatment, but the fact that the combination formulation may be too only after each individual component has been tipotent for initiating therapy. These problems may be trated to the appropriate level ( the concept implies that a fixed-dose combination formulation will be available with the appropriate dosage determined with monotherapy titrations ) . ously [24] [25] [26] [27] in the same trial. From a statistical point of view, these experiments are highly efficient for they permit precise characterization of dose-response and dose-toxicity relationships. Therefore, they also enable identification of an optimal dose ratio of the two agents in combination for purposes of both safety and effectiveness.
There are new ACE inhibitor / calcium channel blocker ( CCB ) combinations available that employ low doses of both components ( benazepril plus amlodipine, enalapril plus felodipine, enalapril plus diltiazem, and trandolapril plus verapamil ) and cough is still observed -these combinations are not approved for initial monotherapy. 28 A similar observation has been made with a very-low-dose combination therapy is possible. First-line antihypertensive treatment approvals for a fixed-dose combination were granted to two diblockers are used as monotherapy in blacks, where uretic / b-blocker formulations, 18 low-dose chlorthalithey appear to be less effective. In addition, each component of a combination product We evaluated the low dose HCTZ ( diuretic ) / bisopromust be shown to be contributing to the therapeutic lol ( b-blocker ) formulation in two studies. 29, 30 effect desired. 17 Other requirements for approval deal In the first study, which used a factorial design, 29 with adverse drug reactions. There are adverse reactions that are dose-related and those that are dose-independent ( within the therapeutic dose range ) . For exam- Reproduced from Frishman WH et al, 29 with permission.
512 patients with stage I and stage II hypertension duced significantly less hypokalemia and less of an increase in uric acid levels than a dosage of 25 mg were randomized in a 12-week placebo-controlled multicenter trial that assessed the antihypertensive ef-daily. The low-dose combination of 2.5 mg daily bisoprolol and 6.25 mg HCTZ daily reduced diastolic fectiveness and safety of once-daily administration of 2.5, 10, or 40 mg of bisoprolol used alone or in combi-blood pressure to õ90 mm Hg in 61% of patients and demonstrated a safety profile that compared favornation with 6.25 or 25 mg of HCTZ. The effects of bisoprolol and HCTZ were additive with respect to ably with that of placebo, fulfilling the second criteria for first-line approval. Side effects were reduced with reduction in diastolic and systolic blood pressures ( Tables 2, 3 ) , fulfilling the first requirement for first-the combination compared to higher dose monotherapies and similar or better blood pressure control was line approval of a fixed-dose combination. The addition of HCTZ ( or bisoprolol ) to therapy with bisopro-achieved with a low-dose combination.
The second study was a trial of 509 stage I and stage lol ( or HCTZ ) produced an incremental reduction in blood pressure. A HCTZ dosage of 6.25 mg daily pro-II hypertensive patients using a placebo-controlled, 30 which as-titrated to achieve maximal blood pressure-reducing response. Blood pressure was measured for efficacy sessed the antihypertensive effectiveness and safety of once-daily administration of 5 mg bisoprolol used response 24 h after the drug dose. The study consisted of a 4-to 5-week placebo run-in phase, a 4-week dose alone or in combination with 6.25 mg thiazide and compared these treatments to placebo and 25 mg escalation phase, and an 8-week maintenance phase.
The study showed a comparable blood pressure re-HCTZ. The combination produced greater blood pressure-lowering effects than 5 mg bisoprolol alone, pla-ducing effect to maximally titrated bisoprolol / HCTZ and amlodipine ( 013.4 / 010.7 mm Hg and 012.8 / cebo, or 25 mg HCTZ, with a side effect profile of the combination comparable to placebo. Less than 1% of 010.2 mm Hg respectively ) . Seventy-one percent of HCTZ / bisoprolol patients and 69% of amlodipine pasubjects on the combination developed hypokalemia ( õ 3.4 mEq / L ) compared to 6.5% taking 25 mg HCTZ tients achieved goal blood pressure ( diastolic blood pressure°90 mm Hg or a decrease in diastolic blood once daily.
The results of these studies reveal that a very-low-pressure ¢ 10 mm Hg ) . In contrast, only 45% of enalapril-treated patients achieved the blood pressure goal dose diuretic / b-blocker formulation can be used as initial monotherapy with therapeutic effects compara-with a reduction of 07.3 / 06.6 mm Hg, significantly less of a blood pressure response than with amlodible to those observed with high-dose monotherapy with either component and with a side effect profile pine or bisoprolol / HCTZ ( enalapril effect might have been better if the drug had been used twice daily ) . similar to placebo. Thus far, there are no long-term morbidity and mortality trials with the low-dose comThere were 29 adverse experiences with the bisoprolol / HCTZ combination, 42 with amlodipine, and 47 bination. Moderate or high-dose diuretics and bblockers have been shown to reduce vascular events with enalapril. One patient in the bisoprolol / HCTZ group dropped out because of adverse experiences in patients with systolic and diastolic hypertension as well as in those with isolated systolic hypertension. compared to four in each of the other groups. Finally, in this study, while minor positive changes in qualityThe low-dose combination appears to be equally efficacious as an antihypertensive agent in black and of-life scores were noted for bisoprolol / HCTZ and amlodipine the changes were not significant. white patients, young and old patients, and men and women. 29, 30 There are no published studies describing Tables 4, 5 , and 6 summarize the results of several comparative studies with bisoprolol / HCTZ and varithe additive effects of the low-dose combination formulation when added to other antihypertensive drugs ous other antihypertensive medications.
31,34 Table 5 compares a second study that evaluated the blood pres-( ACE inhibitors or calcium blockers ) .
sure lowering effects of a CCB, an ACE inhibitor, and COMPARISON OF VERY-LOW-DOSE DIURETIC a b-blocker/HCTZ combination with the first study COMBINATIONS TO OTHER MONOTHERAPY quoted above. 34 As noted, blood pressure response and REGIMENS response rates with the combination were as good or better than with the other antihypertensive agents, and The very-low-dose HCTZ / b-blocker combination was also compared to standard doses of various mo-adverse reactions were similar to placebo. notherapies in two recent studies.
31

OPEN LABEL STUDY
In the first study, 218 patients with stage 1 and stage 2 hypertension were randomized into a placebo run-In an open label trial, 13,700 patients with stage I and stage II hypertension were randomized to receive biin, active-control, double-blind, dose-escalation trial comparing three once-daily doses of bisoprolol / soprolol / HCTZ ( 2.5 / 6.25 mg and 5 / 6.25 mg ) or one of several different ACE inhibitors ( ramipril, quin-HCTZ ( 2.5 / 6.25, 5 / 6.25, 10 / 6.25 mg ) to amlodipine ( 2.5, 5, and 10 mg ) and enalapril ( 5, 10, and 20 mg ) april, benazepril, enalapril, lisinopril, and others ) . Drugs were titrated to achieve blood pressure control outcomes. Several have included the use of diuretics with a b-blocker added if goal pressure was not over a 6-week treatment period. At the study's end, 72% of bisoprolol / HCTZ and 68% of ACE inhibitor achieved. 32 In situations where patient compliance is an issue or where initial BP ú 155 to 160 / 95 to 100 treated patients achieved blood pressure control ( diastolic blood pressure õ 90 mm Hg or ¢ 10% reduction mm Hg, especially if target organ involvement is noted, it would seem appropriate to try a low-dose diuretic / in diastolic blood pressure ) . The bisoprolol / HCTZ combination reduced blood pressure regardless of b-blocker combination, followed by a higher-dose combination regimen if necessary. The available data indirace, gender, or age and was well tolerated and associated with a low rate of patients who discontinued cate that such therapy may result in a better outcome. therapy.
SUMMARY AND CONCLUSION CLINICAL SITUATIONS WHERE
Diuretics and b-blockers have been used in combina-COMBINATION DIURETIC/b-BLOCKER tion as separate medications for many years and also THERAPY CAN BE RECOMMENDED as single fixed-dose formulations. A combination has the advantage of providing greater efficacy than sinThere are no studies where fixed-dose combination formulations have been used in morbidity and mortality gle drugs as monotherapy, and negates some of the 
